Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 12%
Buy 18%
Hold 65%
Sell 6%
Strong Sell 0%

Bulls say

Amgen is well-positioned for sustained growth with a robust pipeline of approved drugs and promising candidates, particularly Uplizna in the rare disease segment. The company's financials are strong with increasing revenues and a dedicated focus towards innovation, signifying its long-term strength. Although there may be some near-term challenges due to patent expiration for certain drugs, the company's ongoing efforts in business development can lead to potential growth opportunities in the future.

Bears say

Amgen is facing declining revenue and potential market share loss due to challenges in their key drugs such as Enbrel and Wezlana, as well as upcoming biosimilar competition for their flagship drug Repatha. Additionally, the company's acquisitions and pipeline drugs may not be enough to offset these challenges, leading to a negative outlook for their stock and financial performance in the near future.

Amgen (AMGN) has been analyzed by 17 analysts, with a consensus rating of Hold. 12% of analysts recommend a Strong Buy, 18% recommend Buy, 65% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 17 analysts, Amgen (AMGN) has a Hold consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $356.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $356.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.